Skip to Main Content

Publications

Ranbaxy Revisited: Rejecting the Performance-based Approach to No-injury Class Actions?

August 2019 - DRI's For The Defense
Social Logo Social Logo Social Logo

One of the basic principles of federal law is that under Article III, one must suffer an injury to have standing to sue. Therefore, when consumers purchase a drug, it performs as intended, and then they turn around and bring a class action against the manufacturer, “something is rotten in the state of [New Jersey].” W. Shakespeare, Hamlet, Prince of Denmark, act 1, scene 4, line 90. Yet “no-injury” class actions are increasingly common, and members of the plaintiffs’ bar prepare to file class action lawsuits the moment that a recall of a prescription drug is announced.

Read the article here.

Driverless
A podcast that analyzes legal issues surrounding autonomous vehicles.
ERISA
Perspectives on employee benefits, executive compensation and ERISA litigation to help you attract and retain talent.
lingua negoti
The language of business.
Ohio Environmental
Insights and commentary for the business and legal community.